Literature DB >> 12081663

Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia.

G A Higgins1, M Enderlin, R Fimbel, M Haman, A J Grottick, M Soriano, J G Richards, J A Kemp, R Gill.   

Abstract

The purpose of these studies were threefold. Firstly, to further characterize the effect of perforant path transection on a test of short-term memory: delayed matching (or nonmatching)-to-position [D(N)MTP]. Secondly, to evaluate the effect of a transient cerebral ischaemia in the same task. Both surgical procedures were chosen as they produce a CNS lesion similar to that described in Alzheimer's Disease (AD). Thirdly, the effect of the acetylcholinesterase inhibitor, donepezil (Aricept(R), E2020), on the resulting cognitive impairment was studied. Perforant path transection produced a robust, delay-dependent impairment of choice accuracy in rats performing either a delayed matching- or nonmatching-to-position task. Sample latency was also reduced following lesion, yet the lesion-induced impairment was not affected by increasing the response requirement at the sample stage. An 11-min period of transient ischaemia (two-vessel occlusion model) resulted in almost complete loss of hippocampal CA1 pyramidal cells and a delay-dependent impairment in DMTP performance. However, unlike perforant path lesions, this deficit was unstable and declined in magnitude over the experimental period. Increasing the delay interval restored this deficit. Donepezil, at doses that robustly attenuated a scopolamine (0.06 mg/kg s.c.)-induced DMTP accuracy impairment in naïve, unoperated rats, had no effect against either lesion-induced impairment. The results are considered in terms of the effectiveness of acetylcholinesterase inhibitors in noncholinergic-based preclinical cognitive models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081663     DOI: 10.1046/j.1460-9568.2002.02018.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  10 in total

Review 1.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

2.  Cognitive performance of healthy young rats following chronic donepezil administration.

Authors:  Debora Cutuli; Francesca Foti; Laura Mandolesi; Paola De Bartolo; Francesca Gelfo; Francesca Federico; Laura Petrosini
Journal:  Psychopharmacology (Berl)       Date:  2008-02-29       Impact factor: 4.530

3.  Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.

Authors:  Latha Ramakrishnan; Christina Amatya; Cassie J DeSaer; Zachary Dalhoff; Michael R Eggerichs
Journal:  Invert Neurosci       Date:  2014-01-09

4.  Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice.

Authors:  John G Csernansky; Maureen Martin; Renu Shah; Amy Bertchume; Jenny Colvin; Hongxin Dong
Journal:  Neuropsychopharmacology       Date:  2005-12       Impact factor: 7.853

5.  Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping.

Authors:  Mark D Lindner; John B Hogan; Donald B Hodges; Anitra F Orie; Ping Chen; Jason A Corsa; John E Leet; Kevin W Gillman; Gregory M Rose; Kelli M Jones; Valentin K Gribkoff
Journal:  Psychopharmacology (Berl)       Date:  2006-09-27       Impact factor: 4.530

6.  Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.

Authors:  Joseph A Araujo; Nigel H Greig; Donald K Ingram; Johan Sandin; Christina de Rivera; Norton W Milgram
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.

Authors:  Theresa M Ballard; Frédéric Knoflach; Eric Prinssen; Edilio Borroni; Jeffrey A Vivian; Jennifer Basile; Rodolfo Gasser; Jean-Luc Moreau; Joseph G Wettstein; Bernd Buettelmann; Henner Knust; Andrew W Thomas; Gerhard Trube; Maria-Clemencia Hernandez
Journal:  Psychopharmacology (Berl)       Date:  2008-10-21       Impact factor: 4.530

8.  Attenuation in rats of impairments of memory by scopolamine, a muscarinic receptor antagonist, by mecamylamine, a nicotinic receptor antagonist.

Authors:  L A Newman; P E Gold
Journal:  Psychopharmacology (Berl)       Date:  2015-12-10       Impact factor: 4.530

9.  Mild cognitive impairment: animal models.

Authors:  Giancarlo Pepeu
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

10.  Bushen‑Yizhi formula ameliorates cognition deficits and attenuates oxidative stress‑related neuronal apoptosis in scopolamine‑induced senescence in mice.

Authors:  Xue-Qin Hou; Dian-Wei Wu; Chun-Xia Zhang; Rong Yan; Cong Yang; Cui-Ping Rong; Lei Zhang; Xiang Chang; Ru-Yu Su; Shi-Jie Zhang; Wen-Qing He; Zhao Qu; Shi Li; Zi-Ren Su; Yun-Bo Chen; Qi Wang; Shu-Huan Fang
Journal:  Int J Mol Med       Date:  2014-06-11       Impact factor: 4.101

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.